Literature DB >> 19729207

'7TM receptor allostery: putting numbers to shapeshifting proteins.

Terry P Kenakin1.   

Abstract

Protein allosterism is the change in protein reactivity at one site arising from a molecule binding on the protein at another site. Although allosterism traditionally has been discussed in terms of affinity changes of receptors, the increasing use of functional pharmacological assays makes it mandatory to consider effects on both the affinity and the efficacy. Antagonism of agonist response can occur allosterically by reduction of affinity and/or efficacy but the antagonist will have different properties depending on which of these is primarily affected. This paper discusses the collective behaviors of seven transmembrane (7TM) receptors as allosteric systems that have a modulator (ligand or protein) that interacts and transmits information through a conduit (receptor) to a guest (either other ligand, interacting protein or cytosolic protein). Such receptor allostery can be discussed as vectorial transfers of information from ligand-binding domains ('classical' modulator allosterism) to the cytosol (functional selectivity) and along the plane of the membrane (receptor dimerization).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729207     DOI: 10.1016/j.tips.2009.06.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  49 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Allosteric interactions between δ and κ opioid receptors in peripheral sensory neurons.

Authors:  Kelly A Berg; Matthew P Rowan; Achla Gupta; Teresa A Sanchez; Michelle Silva; Ivone Gomes; Blaine A McGuire; Philip S Portoghese; Kenneth M Hargreaves; Lakshmi A Devi; William P Clarke
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

3.  Agonism/antagonism switching in allosteric ensembles.

Authors:  Hesam N Motlagh; Vincent J Hilser
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-02       Impact factor: 11.205

Review 4.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 5.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 6.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

7.  Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 8.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 9.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

Review 10.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.